Management and delivery of special neurological rehab

Can rehabilitation reduce attendance at Accident and Emergency (A&E) and promote wellbeing for people with severe epilepsy? A multicentre non-randomised interventional treatment trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN06469947

Enrollment

170

Registered

2010-05-21

Start date

2009-06-04

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Neurological, Primary Care Research Network for England

Interventions

The intervention will start with the offer of a clinic appointment with a nurse with special interest in epilepsy after the patient has been discharged following an A&E attendance. The nurse will asse

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Be aged 18 years or over, either sex 2. Have epilepsy that has been diagnosed and treated with medication 3. Be able to communicate in English sufficiently to complete questionnaires 4. Be resident and registered with a GP in either Southwark or Lambeth PCT

Exclusion criteria

Exclusion criteria: 1. Having no diagnosis; new epilepsy leads to a referral to a neurologist 2. Having already seen a specialist nurse for epilepsy in the prior year 3. Alcohol or other substance misuse 4. Other severe medical illness, such as psychosis or terminal cancer

Design outcomes

Primary

Measure	Time frame
Accident and Emergency re-attendance, measured at baseline, 6 and 12-month follow-up.	—

Secondary

Measure	Time frame
1. Seizure frequency, measured at baseline and 6 month follow-up 2. Seizure severity, measured at baseline and 6 month follow-up 3. Seizure impact, measured at baseline and 6 month follow-up 4. Psychological distress, measured at baseline, 6 and 12-month follow-up 5. Perceived stigmatisation, measured at baseline and 6 month follow-up 6. Quality of life, measured at baseline, 6 and 12-month follow-up 7. Self efficacy in managing epilepsy, measured at baseline, 6 and 12-month follow-up 8. Medication adherence, measured at baseline, 6 and 12-month follow-up 9. Satisfaction with information about medications, measured at baseline and 6 month follow-up 10. Knowledge of epilepsy, measured at baseline and 6 month follow-up 11. Quality-adjusted life years (QALYs), measured at baseline, 6 and 12-month follow-up	—

Measure

Time frame

1. Seizure frequency, measured at baseline and 6 month follow-up 2. Seizure severity, measured at baseline and 6 month follow-up 3. Seizure impact, measured at baseline and 6 month follow-up 4. Psychological distress, measured at baseline, 6 and 12-month follow-up 5. Perceived stigmatisation, measured at baseline and 6 month follow-up 6. Quality of life, measured at baseline, 6 and 12-month follow-up 7. Self efficacy in managing epilepsy, measured at baseline, 6 and 12-month follow-up 8. Medication adherence, measured at baseline, 6 and 12-month follow-up 9. Satisfaction with information about medications, measured at baseline and 6 month follow-up 10. Knowledge of epilepsy, measured at baseline and 6 month follow-up 11. Quality-adjusted life years (QALYs), measured at baseline, 6 and 12-month follow-up

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026